AstraZeneca/Daiichi Make Their Case For Dato-DXd In Non-Squamous Lung Cancer
Early-Stage PD-L1/Chemo Combo Data Also Reported
Data at WCLC showed why the TROP2-targeting ADC datopotamab deruxtecan is most effective in non-squamous NSCLC in second or later lines as presented in overall survival data at the meeting.
